A novel unexpected pyrazolo[1,5‐a]pyrimidine‐based Cu(I) complex, [Cu (DQPC)2]ClO4, has been synthesized by reaction of 2,7‐diamino‐5‐phenyl‐3‐(phenyldiazenyl)pyrazolo[1,5‐a]pyrimidine‐6‐carbonitrile (DQPC) and Cu (ClO4)2.6H2O in ethanol. Full characterizations of [Cu (DQPC)2]ClO4 are achieved via CHNCu‐analyses, Ʌm calculation, spectroscopic techniques, and confirmed unambiguously by single crystal X‐ray diffraction. The crystallographic data revealed a distorted tetrahedral environment around the Cu(I) center in the inner sphere, where the (DQPC) acted as a neutral bidentate ligand, while one perchlorate ion, in the outer sphere. [Cu (DQPC)2]ClO4 and DQPC have been screened against six pathogenic microorganisms and breast carcinoma human cancer cell lines (MCF‐7). The data revealed high anti‐bacterial, anti‐fungal, and interesting cytotoxic activities. Furthermore, [Cu (DQPC)2]ClO4 showed significant cell growth inhibition activity (IC50 = 0.89 ± 0.06 μg/ml), even higher than the standard anticancer drugs; cisplatin (IC50 = 5.71 ± 0.55 μg/ml); and vinblastine sulfate (IC50 = 5.44 ± 0.64 μg/ml), while DQPC itself has the lowest cytotoxicity (IC50 = 9.9 ± 1.4 μg/ml). DNA binding study showed that DQPC and [Cu (DQPC)2]ClO4 strongly bind to DNA, presumably via intercalation and electrostatic mechanisms.